Unknown

Dataset Information

0

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.


ABSTRACT: BACKGROUND:In the phase III RECOURSE trial, trifluridine/tipiracil (TAS-102) extended overall survival (OS) and progression-free survival (PFS) with an acceptable toxicity profile in patients with metastatic colorectal cancer refractory or intolerant to standard therapies. The present analysis investigated the efficacy and safety of trifluridine/tipiracil in RECOURSE subgroups. METHODS:Primary and key secondary end-points were evaluated using a Cox proportional hazards model in prespecified subgroups, including geographical subregion (United States of America [USA], European Union [EU], Japan), age (<65 years, ?65 years) and v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homologue (KRAS) status (wild type, mutant). Safety and tolerability were reported with descriptive statistics. RESULTS:Eight-hundred patients were enrolled: USA, n = 99; EU, n = 403; Japan, n = 266. Patients aged ?65 years and those with mutant KRAS tumours comprised 44% and 51% of all patients in the subregions, respectively. Final OS analysis (including 89% of events, compared with 72% in the initial analysis) confirmed the survival benefit associated with trifluridine/tipiracil, with a hazard ratio (HR) of 0.69 (95% confidence interval [CI] 0.59-0.81; P = 0.0001). Median OS in the three regions was 6.5-7.8 months in the trifluridine/tipiracil arm and 4.3-6.7 months in the placebo arm (USA: HR 0.56; 95% CI 0.34-0.94; P = 0.0277; EU: HR 0.62; 95% CI 0.48-0.80; P = 0.0002; Japan: HR 0.75; 95% CI 0.57-1.00; P = 0.0470). Median PFS was 2.0-2.8 months for trifluridine/tipiracil and 1.7-1.8 months for placebo; HRs favoured trifluridine/tipiracil in all regions. Similar clinical benefits of trifluridine/tipiracil were observed in elderly patients and in those with mutant KRAS tumours. There were no marked differences among subregions in terms of safety and tolerability. CONCLUSIONS:Trifluridine/tipiracil was effective in all subgroups, regardless of age, geographical origin or KRAS status. This trial is registered with ClinicalTrials.gov: NCT01607957.

SUBMITTER: Van Cutsem E 

PROVIDER: S-EPMC7493695 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.

Van Cutsem Eric E   Mayer Robert J RJ   Laurent Stéphanie S   Winkler Robert R   Grávalos Cristina C   Benavides Manuel M   Longo-Munoz Federico F   Portales Fabienne F   Ciardiello Fortunato F   Siena Salvatore S   Yamaguchi Kensei K   Muro Kei K   Denda Tadamichi T   Tsuji Yasushi Y   Makris Lukas L   Loehrer Patrick P   Lenz Heinz-Josef HJ   Ohtsu Atsushi A  

European journal of cancer (Oxford, England : 1990) 20171221


<h4>Background</h4>In the phase III RECOURSE trial, trifluridine/tipiracil (TAS-102) extended overall survival (OS) and progression-free survival (PFS) with an acceptable toxicity profile in patients with metastatic colorectal cancer refractory or intolerant to standard therapies. The present analysis investigated the efficacy and safety of trifluridine/tipiracil in RECOURSE subgroups.<h4>Methods</h4>Primary and key secondary end-points were evaluated using a Cox proportional hazards model in pr  ...[more]

Similar Datasets

| S-EPMC5239803 | biostudies-literature
| S-EPMC5352756 | biostudies-literature
| S-EPMC9749246 | biostudies-literature
| S-EPMC10215810 | biostudies-literature
| S-EPMC7440836 | biostudies-literature
| S-EPMC8316169 | biostudies-literature
| S-EPMC7491979 | biostudies-literature
| S-EPMC8658167 | biostudies-literature
| S-EPMC5537908 | biostudies-literature
| S-EPMC8637322 | biostudies-literature